| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTZ |
| Uniprot No | O15234 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-703aa |
| 氨基酸序列 | MADRRRQRAS QDTEDEESGA SGSDSGGSPL RGGGSCSGSA GGGGSGSLPS QRGGRTGALH LRRVESGGAK SAEESECESE DGIEGDAVLS DYESAEDSEG EEGEYSEEEN SKVELKSEAN DAVNSSTKEE KGEEKPDTKS TVTGERQSGD GQESTEPVEN KVGKKGPKHL DDDEDRKNPA YIPRKGLFFE HDLRGQTQEE EVRPKGRQRK LWKDEGRWEH DKFREDEQAP KSRQELIALY GYDIRSAHNP DDIKPRRIRK PRYGSPPQRD PNWNGERLNK SHRHQGLGGT LPPRTFINRN AAGTGRMSAP RNYSRSGGFK EGRAGFRPVE AGGQHGGRSG ETVKHEISYR SRRLEQTSVR DPSPEADAPV LGSPEKEEAA SEPPAAAPDA APPPPDRPIE KKSYSRARRT RTKVGDAVKL AEEVPPPPEG LIPAPPVPET TPTPPTKTGT WEAPVDSSTS GLEQDVAQLN IAEQNWSPGQ PSFLQPRELR GMPNHIHMGA GPPPQFNRME EMGVQGGRAK RYSSQRQRPV PEPPAPPVHI SIMEGHYYDP LQFQGPIYTH GDSPAPLPPQ GMLVQPGMNL PHPGLHPHQT PAPLPNPGLY PPPVSMSPGQ PPPQQLLAPT YFSAPGVMNF GNPSYPYAPG ALPPPPPPHL YPNTQAPSQV YGGVTYYNPA QQQVQPKPSP PRRTPQPVTI KPPPPEVVSR GSS |
| 预测分子量 | 76,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与BTZ(Bortezomib)及重组蛋白技术相关的文献摘要，涵盖不同研究方向：
---
1. **文献名称**: *Structural basis of proteasome inhibition by antitumor drug Bortezomib*
**作者**: Groll M, et al.
**摘要**: 通过重组表达人源26S蛋白酶体核心亚基，结合X射线晶体学解析了Bortezomib与蛋白酶体活性位点的相互作用，揭示了其选择性抑制机制，为优化类似药物提供结构基础。
---
2. **文献名称**: *Recombinant immunoproteasome subunits for targeted cancer therapy*
**作者**: Chen X, et al.
**摘要**: 研究团队利用重组技术表达免疫蛋白酶体亚基LMP2/LMP7.发现Bortezomib对其抑制效率低于组成型蛋白酶体，解释了药物对特定肿瘤细胞的选择性毒性，为精准治疗提供新策略。
---
3. **文献名称**: *Enhancing Bortezomib delivery via recombinant protein-based nanoparticles*
**作者**: Wang Y, et al.
**摘要**: 开发重组白蛋白-脂质融合蛋白纳米颗粒，显著提升Bortezomib的肿瘤靶向性和溶解性，在骨髓瘤模型中展现增强的抗癌效果与降低的神经毒性，为改善药物递送系统提供新思路。
---
**备注**：若需更具体的文献方向(如基础机制、临床转化等)，可进一步补充关键词调整检索策略。
The BTZ recombinant protein is a biotechnologically engineered molecule primarily associated with proteasome inhibition studies, particularly in cancer research. Derived from the boronic acid dipeptide structure of Bortezomib (BTZ), a clinically approved proteasome inhibitor, this recombinant protein is designed to mimic or enhance the drug's interaction with the 20S proteasome complex. It is commonly produced using recombinant DNA technology in expression systems like *E. coli* or mammalian cells, enabling scalable production for research and therapeutic development.
BTZ targets the chymotrypsin-like activity of proteasomes, disrupting protein degradation in cells. This mechanism is critical in malignancies like multiple myeloma, where cancer cells rely heavily on proteasome function. The recombinant version allows precise modification of BTZ's pharmacophore or conjugation to delivery vehicles (e.g., antibodies, nanoparticles) to improve tumor specificity and reduce off-target effects. Researchers utilize it to study drug resistance mechanisms, optimize binding kinetics, and develop next-generation proteasome inhibitors.
Beyond oncology, BTZ recombinant proteins contribute to neurodegenerative disease models, where proteasome dysfunction plays a role. They also serve as tools for structural biology, aiding in cryo-EM studies to map drug-proteasome interactions. Challenges include maintaining post-translational modifications in heterologous expression systems and balancing inhibition potency with cellular toxicity. Ongoing work focuses on engineering variants with enhanced blood-brain barrier penetration for CNS applications or reduced immunogenicity for sustained therapies. This recombinant platform bridges drug discovery and molecular pathology, offering insights into both disease mechanisms and therapeutic optimization.
×
